16 Oct 2025 | 3 Mins Read
Rubicon Research IPO may debut with over 30% premium
Flipitmoney
Rubicon Research, a pharmaceutical formulations company, makes its Dalal Street debut on October 16 with a listing gain of around 31%. Its ₹1,377.5-crore IPO, subscribed 104 times, attracted over 31.42 lakh applications with bids worth ₹82,900 crore. The company will list with a promoter stake of about 35% post-listing.